The initial treatment of Parkinson's disease should begin with levodopa

被引：0
|
作者：
Weiner, WJ [1 ]
机构：
[1] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA
来源：
MOVEMENT DISORDERS | 1999年 / 14卷 / 05期
关键词：
Parkinson's disease; levodopa; dopamine receptor agonists; toxicity; levodopa-sparing strategies;
D O I：
10.1002/1531-8257(199909)14:5<716::AID-MDS1002>3.0.CO;2-Q
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
For over two decades controversy has surrounded the initial choice of therapeutic agent for patients with early symptomatic Parkinson's disease. Whether levodopa or dopa mine receptor agonist monotherapy in these patients is more efficacious and/or results in fewer long-term complications of dopaminergic therapy such as motor fluctuations, dyskinesias, or psychiatric disorders is unresolved. This article examines the evidence related to levodopa-sparing strategies and levodopa-induced toxicity in Parkinson's disease. At this time, then is little evidence to support levodopa-sparing strategies or to suggest that levodopa is toxic and harmful to patients with Parkinson's disease.
引用
收藏
页码：716 / 724
页数：9
相关论文
共 50 条
  • [41] Initial treatment of Parkinson's disease
    Tarsy D.
    [J]. Current Treatment Options in Neurology, 2006, 8 (3) : 224 - 235
  • [42] Initial experience with levodopa intestinal gel for advanced Parkinson's disease
    Cohen, O. S.
    Yahalom, G.
    Strauss, H.
    Faust-Socher, A.
    Lang, A.
    Lerman, S. F.
    Baer, S. Hassin
    [J]. MOVEMENT DISORDERS, 2014, 29 : S137 - S137
  • [43] Levodopa and Parkinson's disease
    Valkovic, P.
    Blazicek, P.
    Benetin, J.
    Kukumberg, P.
    [J]. CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2006, 69 (03) : 183 - 188
  • [44] Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study
    Caraceni, T
    Musicco, M
    [J]. PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) : 107 - 114
  • [45] Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
    Holloway, R
    Shoulson, I
    Kieburtz, K
    McDermott, M
    Tariot, P
    Kamp, C
    Day, D
    Shinaman, A
    Fahn, S
    Lang, A
    Marek, K
    Seibyl, J
    Weiner, W
    Welsh, M
    Pahwa, R
    Coe, S
    Barclay, L
    Sutherland, L
    Hildebrand, K
    Hubble, J
    Weeks, C
    LeWitt, P
    Miyasaki, J
    Duff, J
    Sime, E
    Suchowersky, O
    Stacy, M
    Kurth, M
    Brewer, M
    Harrigan, M
    Russell, DS
    Fussell, B
    Ford, B
    Dillon, S
    Hammerstad, J
    Stone, C
    Riley, D
    Rainey, P
    Standaert, D
    Tennis, M
    Wooten, F
    Rost-Ruffner, E
    Factor, S
    Brown, D
    Jankovic, J
    Atassi, F
    Kurlan, R
    Gardiner, I
    Panisset, M
    Amyot, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (15): : 1931 - 1938
  • [46] Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri, K. Ray
    Jenner, Peter
    Antonini, Angelo
    [J]. MOVEMENT DISORDERS, 2019, 34 (06) : 816 - 819
  • [47] Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
    Frackiewicz, EJ
    Jhee, SS
    Shiovitz, TM
    Webster, J
    Topham, C
    Dockens, RC
    Whigan, D
    Salazar, DE
    Cutler, NR
    [J]. ANNALS OF PHARMACOTHERAPY, 2002, 36 (02) : 225 - 230
  • [48] The effects of Nardosinone on levodopa intervention in the treatment of Parkinson's disease
    Liu, Mengmeng
    Xue, Jingwen
    Cao, Yuxin
    Hao, Zhuangzhuang
    Wang, Yuqing
    Li, Jiayuan
    Jiang, Tingyue
    Shi, Jinli
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [49] History of levodopa and dopamine agonists in Parkinson's disease treatment
    Tolosa, E
    Martí, MJ
    Valldeoriola, F
    Molinuevo, JL
    [J]. NEUROLOGY, 1998, 50 (06) : S2 - S10
  • [50] The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
    Schapira, Anthony H. V.
    [J]. MOVEMENT DISORDERS, 2008, 23 : S515 - S520
12345